BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $REGN readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07431086-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Olatorepatide readout (P2) · Regeneron Pharmaceuticals $REGN
DESCRIPTION:Study of Olatorepatide in Adult Participants Living With Overwe
 ight or Obesity in the US\n\nPrimary completion date: 2026-11-13 (estimate
 d)\nPhase 2 · Cardio-Met · Overweight or Obesity\nEnrollment: 120 · Sit
 es: 3\n\nPrimary completion = last participant's primary-endpoint data col
 lected\; topline results usually follow weeks to months later. Sponsor-rep
 orted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.ne
 tlify.app/radar.html?nct=NCT07431086\nhttps://clinicaltrials.gov/study/NCT
 07431086
URL:https://datacutoff.com/radar.html?nct=NCT07431086
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06421636-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:FERVENT-1 readout (P2) · Regeneron Pharmaceuticals $REGN
DESCRIPTION:A Study to Test the Safety\, Tolerability\, and Efficacy of an 
 Antibody\, REGN7999\, Injected Under the Skin for the Treatment of Iron Ov
 erload in Adult Participants With Non-Transfus…\n\nPrimary completion da
 te: 2026-12-03 (estimated)\nOriginally planned: 2028-01-24 (-13.7 months)\
 nPhase 2 · Rare · Non-Transfusion Dependent Beta-Thalassemia (NTDT)\nEnr
 ollment: 19 · Sites: 26\n\nPrimary completion = last participant's primar
 y-endpoint data collected\; topline results usually follow weeks to months
  later. Sponsor-reported\, often an estimate. Not investment advice.\n\nht
 tps://trialsonar.netlify.app/radar.html?nct=NCT06421636\nhttps://clinicalt
 rials.gov/study/NCT06421636
URL:https://datacutoff.com/radar.html?nct=NCT06421636
CATEGORIES:Rare,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477704-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261229
DTEND;VALUE=DATE:20261230
SUMMARY:ASCEND-QW readout (P2) · Regeneron Pharmaceuticals $REGN
DESCRIPTION:A Study to See How Safe and Effective Alirocumab is When Given 
 Weekly to Adult Participants Who Have Hypercholesterolemia\n\nPrimary comp
 letion date: 2026-12-29 (estimated)\nOriginally planned: 2026-10-20 (+2.3 
 months)\nPhase 2 · Cardio-Met · Hypercholesterolemia\nEnrollment: 438 ·
  Sites: 34\n\nPrimary completion = last participant's primary-endpoint dat
 a collected\; topline results usually follow weeks to months later. Sponso
 r-reported\, often an estimate. Not investment advice.\n\nhttps://trialson
 ar.netlify.app/radar.html?nct=NCT07477704\nhttps://clinicaltrials.gov/stud
 y/NCT07477704
URL:https://datacutoff.com/radar.html?nct=NCT07477704
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608291-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Fianlimab readout (P3) · Regeneron Pharmaceuticals $REGN
DESCRIPTION:A Trial to See if the Combination of Fianlimab With Cemiplimab 
 Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From C
 oming Back After it Has Been Removed With …\n\nPrimary completion date: 
 2027-01-15 (estimated)\nOriginally planned: 2029-10-11 (-32.9 months)\nPha
 se 3 · Oncology · Melanoma\nEnrollment: 1564 · Sites: 211\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://datacutoff.com/radar.htm
 l?nct=NCT05608291\nhttps://clinicaltrials.gov/study/NCT05608291
URL:https://datacutoff.com/radar.html?nct=NCT05608291
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175428-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:ROXI-ATLAS readout (P2) · Regeneron Pharmaceuticals $REGN
DESCRIPTION:Safety in Adult Participants With Atrial Fibrillation Who Are T
 reated With Anticoagulation\n\nPrimary completion date: 2027-02-09 (estima
 ted)\nOriginally planned: 2027-04-26 (-2.5 months)\nPhase 2 · Cardio-Met 
 · Atrial Fibrillation (AF)\nEnrollment: 1200 · Sites: 91\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT07175428\nhttps://clinicaltrials.gov/study/NCT07175428
URL:https://datacutoff.com/radar.html?nct=NCT07175428
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015905-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:ROXI-APEX readout (P3) · Regeneron Pharmaceuticals $REGN
DESCRIPTION:REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis 
 After Total Knee Arthroplasty in Adults\n\nPrimary completion date: 2027-0
 2-20 (estimated)\nPhase 3 · Cardio-Met · Venous Thromboembolism (VTE)\nE
 nrollment: 2000 · Sites: 47\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT07015905\nhttps://clini
 caltrials.gov/study/NCT07015905
URL:https://datacutoff.com/radar.html?nct=NCT07015905
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246916-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:fianlimab readout (P3) · Regeneron Pharmaceuticals $REGN
DESCRIPTION:A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodie
 s in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head
 -to-Head)\n\nPrimary completion date: 2027-03-22 (estimated)\nOriginally p
 lanned: 2027-01-07 (+2.4 months)\nPhase 3 · Oncology · Melanoma\nEnrollm
 ent: 560 · Sites: 113\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://trialsonar.netlify.app/radar.html?nct=NCT06246916\nhttps://clinicaltri
 als.gov/study/NCT06246916
URL:https://datacutoff.com/radar.html?nct=NCT06246916
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07213778-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:ROXI-ASPEN readout (P3) · Regeneron Pharmaceuticals $REGN
DESCRIPTION:REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thrombopr
 ophylaxis After Total Knee Arthroplasty in Adult Participants\n\nPrimary c
 ompletion date: 2027-05-17 (estimated)\nOriginally planned: 2027-07-16 (-2
 .0 months)\nPhase 3 · Cardio-Met · Symptomatic Venous Thromboembolism (V
 TE)\nEnrollment: 2000 · Sites: 57\n\nPrimary completion = last participan
 t's primary-endpoint data collected\; topline results usually follow weeks
  to months later. Sponsor-reported\, often an estimate. Not investment adv
 ice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07213778\nhttps:/
 /clinicaltrials.gov/study/NCT07213778
URL:https://datacutoff.com/radar.html?nct=NCT07213778
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220772-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:Mibavademab readout (P3) · Regeneron Pharmaceuticals $REGN
DESCRIPTION:A Study Evaluating Mibavademab Treatment of Obesity Due to Lept
 in (LEP) Gene Mutations in Children\, Adolescents and Adults\n\nPrimary co
 mpletion date: 2027-06-18 (estimated)\nOriginally planned: 2027-04-09 (+2.
 3 months)\nPhase 3 · Cardio-Met · Monogenic Obesity\nEnrollment: 4 · Si
 tes: 4\n\nPrimary completion = last participant's primary-endpoint data co
 llected\; topline results usually follow weeks to months later. Sponsor-re
 ported\, often an estimate. Not investment advice.\n\nhttps://trialsonar.n
 etlify.app/radar.html?nct=NCT07220772\nhttps://clinicaltrials.gov/study/NC
 T07220772
URL:https://datacutoff.com/radar.html?nct=NCT07220772
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785767-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:fianlimab readout (P2/3) · Regeneron Pharmaceuticals $REGN
DESCRIPTION:A Study to Learn if a Combination of Fianlimab and Cemiplimab V
 ersus Cemiplimab Alone is More Effective for Adult Participants With Advan
 ced Non-Small Cell Lung Cancer (NSCLC)\n\nPrimary completion date: 2027-09
 -28 (estimated)\nOriginally planned: 2028-11-13 (-13.5 months)\nPhase 2/3 
 · Oncology · Advanced Non-Small Cell Lung Cancer\nEnrollment: 149 · Sit
 es: 106\n\nPrimary completion = last participant's primary-endpoint data c
 ollected\; topline results usually follow weeks to months later. Sponsor-r
 eported\, often an estimate. Not investment advice.\n\nhttps://trialsonar.
 netlify.app/radar.html?nct=NCT05785767\nhttps://clinicaltrials.gov/study/N
 CT05785767
URL:https://datacutoff.com/radar.html?nct=NCT05785767
CATEGORIES:Oncology,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
